Straits Times Index
3,323.38 +0.18 (+0.01%) S&P 500
5,235.48 -31.47 (-0.60%) Dow
38,111.48 -330.06 (-0.86%) Nasdaq
16,737.08 -183.50 (-1.08%) Bitcoin USD
68,292.02 +682.88 (+1.01%) CMC Crypto 200
1,430.11 -25.76 (-1.77%)
AZN Jun 2024 77.500 call
| Previous close | 0.8400 |
| Open | 1.0800 |
| Bid | 1.1800 |
| Ask | 1.2300 |
| Strike | 77.50 |
| Expiry date | 2024-06-21 |
| Day's range | 1.0800 - 1.2400 |
| Contract range | N/A |
| Volume | |
| Open interest | 6.23k |
BenzingaAmgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug
Tuesday, the FDA approved Amgen Inc (NASDAQ:AMGN) Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to AstraZeneca Plc’s (NASDAQ:AZN) Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the following treatment indications, which are also currently approved for Soliris: The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-medi
ZacksAstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
AstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival data in a late-stage NSCLC study on Dato-DXd compared with docetaxel.
BenzingaWhy Is AstraZeneca Stock Trading Lower On Tuesday?
On Tuesday, AstraZeneca Plc (NASDAQ:AZN) said the survival results did not reach statistical significance in the overall trial population in the TROPION-Lung01 phase 3 trial. Topline overall survival (OS) results from the TROPION-Lung01 phase 3 trial, which previously met the dual primary endpoint of progression-free survival (PFS), numerically favored datopotamab deruxtecan (Dato-DXd) compared to docetaxel for locally advanced or metastatic non-small cell lung cancer (NSCLC) patients treated wi
